Case Report
Bone Marrow Transplantation (2003) 31, 305–308. doi:10.1038/sj.bmt.1703836
Imatinib mesylate (STI-571) given concurrently with nonmyeloablative stem cell transplantation did not compromise engraftment and resulted in cytogenetic remission in a patient with chronic myeloid leukemia in blast crisis
L P Koh1, W Y K Hwang1, C T H Chuah1, Y C Linn1, Y T Goh1, C H Tan1, H J Ng1 and P H C Tan1
1Department of Haematology, Singapore General Hospital, Singapore
Correspondence: Dr LP Koh, Department of Haematology, Singapore General Hospital, Outram Road, Singapore 169608, Singapore
Received 1 July 2002; Accepted 2 October 2002.
Abstract
The main obstacles to successful hematopoietic stem cell transplantation for patients with chronic myeloid leukemia (CML) in blast crisis (BC) are increased post-transplant relapse and high treatment-related mortality. We report a patient with CML in BC who was treated initially with imatinib mesylate and was then concurrently treated with a nonmyeloablative stem cell transplant. Successful engraftment of donor cells followed by complete cytogenetic remission was achieved in the absence of severe therapy-related toxicities. This case demonstrates that imatinib mesylate given through nonmyeloablative transplant is a minimally toxic therapeutic approach, which does not compromise engraftment and may result in a favorable outcome in patients with CML in BC.
Keywords:
chronic myeloid leukemia, blast crisis, Imatinib, nonmyeloablative stem cell transplantation
